US 11,986,541 B2
Method of preventing the development of melanoma
Peter Novak, Sunny Isles Beach, FL (US); Max Temnik, Miami, FL (US); and Oleksandr Balakin, Dnepropetrovsk (UA)
Assigned to Vector Vitale IP LLC, North Miami Beach, FL (US)
Filed by Vector Vitale IP LLC, North Miami Beach, FL (US)
Filed on Aug. 9, 2023, as Appl. No. 18/232,013.
Application 18/232,013 is a continuation of application No. 17/969,297, filed on Oct. 19, 2022, granted, now 11,730,835.
Application 17/969,297 is a continuation of application No. 16/692,584, filed on Nov. 22, 2019, granted, now 11,484,610, issued on Nov. 1, 2022.
Prior Publication US 2023/0381347 A1, Nov. 30, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 51/04 (2006.01); A61K 31/164 (2006.01); A61K 33/30 (2006.01); A61P 35/00 (2006.01)
CPC A61K 51/0476 (2013.01) [A61K 31/164 (2013.01); A61K 33/30 (2013.01); A61P 35/00 (2018.01)] 5 Claims
 
1. A method of reducing melanoma tumor growth of a primary melanoma in a patient in need thereof, comprising suppressing tumor growth of the primary melanoma by administering a composition comprising a therapeutically effective amount of 64Zne(Asp)2 to said patient wherein from 0.2 ug/kg to 2000 mg/kg patient weight/day of 64Zne(Asp)2 is administered to the patient and; wherein the 64Zne(Asp)2 is at least 90% 64Zn and is administered intratumorally to the primary melanoma of said patient.